RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $28 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Leonid Timashev has reiterated his 'Outperform' rating on Edgewise Therapeutics (NASDAQ:EWTX), maintaining a price target of $28.
June 28, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital's reiteration of an 'Outperform' rating and a $28 price target for Edgewise Therapeutics could potentially boost investor confidence.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, RBC Capital's reiteration of an 'Outperform' rating and a $28 price target for Edgewise Therapeutics (EWTX) could potentially boost investor confidence and positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100